Bicycle Therapeutics’ initial therapeutic focus is in oncology, where it is developing Bicycle Drug Conjugates® (BDCs) for a range of tumour types of high unmet medical need.


BDCs link a toxin payload to a specific high-affinity Bicycle® designed to bind a tumour antigen and take advantage of Bicycles®’ inherent properties of high target specificity, rapid penetration into the tumour and low systemic exposure, combined with liver-sparing rapid renal clearance. The result is much higher molar loading of toxin than seen with other conjugate approaches, coupled to short exposure. Other approaches rely on long exposure to deliver sufficient toxin over time, with associated risk of damage to normal tissue. These alternative approaches also underperform in real-world tumours compared to preclinical models whereas Bicycles should penetrate more complex human tumours independent of tumour architecture and without reliance on tumour vasculature. Finally, BDCs can be designed to address tumour heterogeneity, either through bi-specific targeting or through capitalizing on bystander efficacy with a cleavable linker. This window to optimize for bystander efficacy without dose limiting toxicity is exclusive to bicycles on account of their rapid clearance.  The BDC approach to toxin targeting has the potential to change the treatment paradigm in both solid tumours and haematological cancers.

Bicycle Therapeutics has created a pipeline of preclinical BDCs with plans to move the first of these (MT1 programme) into the clinic within the next 12 months.